Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3

Acute myeloid leukemia (AML) patients with FLT3/ITD mutations have a poor prognosis. Monotherapy with selective FLT3 tyrosine kinase inhibitors (TKIs) have shown transient and limited efficacy due to the development of resistance. Arsenic trioxide (ATO, As(2)O(3)) has been proven effective in treati...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Kozo, Hou, Lihong, Li, Li, Nguyen, Bao, Seale, Tessa, Shirley, Courtney, Ma, Hayley, Levis, Mark, Ghiaur, Gabriel, Duffield, Amy, Small, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152471/
https://www.ncbi.nlm.nih.gov/pubmed/30250637
http://dx.doi.org/10.18632/oncotarget.25972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152471/
https://www.ncbi.nlm.nih.gov/pubmed/30250637
http://dx.doi.org/10.18632/oncotarget.25972

Ejemplares similares